Knappertz Volker 4
4 · Aurinia Pharmaceuticals Inc. · Filed Feb 22, 2024
Insider Transaction Report
Form 4
Knappertz Volker
EVP, Research and Development
Transactions
- Sale
Common Stock
2024-02-20$5.48/sh−25,146$137,800→ 324,058 total
Footnotes (2)
- [F1]Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs granted on August 1, 2022 grant.
- [F2]Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 shares of common stock were acquired on May 31, 2023 and 2,430 shares of common stock were acquired on November 30, 2023.